Xuan Ye

Xuan Ye

Auto-generated profile, based on publicly available information

Xuan Ye

Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Department of Women’s and Children’s Health, Karolinska Institute, Region Stockholm, 17164 Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
ZZZhisheng Zhang
Zhisheng Zhang
HLHuan Li
Huan Li
JZJiacheng Zhang
Jiacheng Zhang
XYXuan Ye
Xuan Ye
HLHongyue Liu
Hongyue Liu
QDQiong Du
Qiong Du
Effect of 3 mg versus 6 mg pegfilgrastim on the prevention of febrile neutropenia in breast cancer patients receiving docetaxel and cyclophosphamide: a retrospective study Zhisheng Zhang, Huan Li, Jiacheng Zhang, Xuan Ye, Hongyue Liu, Qing Zhai, Bo Yu, Qiong Du

7 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
XYXuan Ye
Xuan Ye
DTDiana Tikhomirova
Diana Tikhomirova
MOMarika Oksanen
Marika Oksanen
MGMassimiliano Gaetani
Massimiliano Gaetani
HGHassan Gharibi
Hassan Gharibi
KTKristiina Tammimies
Kristiina Tammimies
Heterogeneous nuclear ribonucleoprotein U (HNRNPU) deficiency is a rare genetic cause of neurodevelopmental disorders (NDDs) lacking targeted therapies. Here, we developed a transcriptomic-guided compound prioritization pipeline using Connectivity Map (CMap) analysis on multi-model transcriptomic signatures from HNRNPU -deficient human cells and mouse models. Ten compounds were selected through manual curation and functionally screened in patient-derived HNRNPU -deficient neuroepithelial stem (NES) cells with earlier observed cellular phenotypes. Two of the compounds, AS601245 and Lenalidomide, significantly reduced the elevated neural progenitor population during differentiation, and their combination further decreased primary cilia incidence, indicating partial rescue of the patient-specific cellular phenotypes. To understand the mechanisms underlying the partial rescue, we employed proteome integral solubility alteration (PISA) and expression proteomics. PISA assay identified TMEM150C and GSK3A as proximal targets of combined treatment. Additionally, we observed reversal of multiple biological pathways including downregulation of Wnt signalling and upregulation of mitochondrial pathways and transmembrane proteins. Altogether, we established a computational-experimental pipeline for transcriptomic-guided drug repurposing for a monogenic NDD, and demonstrated that the network-level modulation partially rescues the delayed neural differentiation in HNRNPU -deficient neural cells.